VRP 1620

Drug Profile

VRP 1620

Alternative Names: Endothelin - Venus Remedies; VRP1620

Latest Information Update: 03 Oct 2016

Price : $50

At a glance

  • Originator University of Illinois
  • Developer Venus Remedies
  • Class Imaging agents
  • Mechanism of Action Endothelin B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 19 Aug 2013 Phase-III clinical trials in Breast cancer (Diagnosis) in India (IV)
  • 27 Apr 2011 Venus Remedies completes enrolment in its phase I/II trial for Breast cancer (diagnosis) in India (CTRI2009-091-001006)
  • 14 Dec 2010 Phase-I/II clinical trials in Breast cancer (Diagnosis) in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top